CA
NZ
UK
AU
IND
US
…
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing therapies that target the soluble guanylate cyclase (sGC) signalling pathway for neurological and cardiopulmonary indications. Long-term growth may be driven by clinical trial progress, regulatory approvals and partnerships to commercialize sGC-modulating programs, and the broader need for new treatments in its target indications which could support uptake.
The company faces material risks from clinical and regulatory failure, limited operating history and revenues, and the need for additional financing amid competitive pressure in both CNS and cardiovascular therapeutic areas.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -3.53M | -3.06M | -12.59M | -44.08M | -51.65M |
| Net income | -3.53M | -3.06M | -5.26M | -43.78M | -51.66M |
| Selling general administrative | 6.09M | 5.34M | 8.13M | 14.50M | 20.62M |
| Selling and marketing expenses | - | - | 0.20M | - | - |
| Gross profit | 2.07M | 2.00M | - | 0.30M | 3.32M |
| Reconciled depreciation | - | - | 0.00M | 0.07M | 0.47M |
| Ebit | - | -3.63M | -9.65M | -44.37M | -55.20M |
| Ebitda | -4.97M | -3.63M | -9.58M | -44.31M | -53.84M |
| Depreciation and amortization | - | - | 0.07M | 0.07M | 1.35M |
| Operating income | -4.97M | -3.63M | -12.95M | -44.37M | -55.20M |
| Other operating expenses | 7.05M | 5.63M | 12.95M | 44.67M | 57.63M |
| Interest expense | - | - | - | 0.29M | 0.02M |
| Interest income | 0.13M | 0.21M | 0.36M | - | - |
| Net interest income | 0.13M | 0.21M | 0.39M | 0.29M | -0.02M |
| Income tax expense | - | - | 8.42M | -0.29M | 0.02M |
| Total revenue | 2.07M | 2.00M | 0.00M | 0.30M | 3.32M |
| Total operating expenses | 7.05M | 5.63M | 12.95M | 44.67M | 57.63M |
| Total other income expense net | 1.45M | 0.57M | 0.36M | 0.29M | 3.55M |
| Net income from continuing ops | -3.53M | -3.06M | -41.05M | -44.08M | -51.65M |
| Net income applicable to common shares | - | - | - | -44.08M | -51.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 9.98M | 9.57M | 13.37M | 18.08M | 59.33M |
| Other current assets | 0.40M | 0.44M | 0.01M | 0.54M | 0.47M |
| Total liab | 0.90M | 0.72M | 2.09M | 7.63M | 11.09M |
| Total stockholder equity | 9.09M | 8.85M | 11.29M | 10.45M | 48.25M |
| Other current liab | 0.39M | 0.34M | 0.89M | 4.66M | 9.26M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -271.02M | -267.49M | -264.42M | -259.15M | -215.08M |
| Other assets | - | - | - | 2.04M | 2.41M |
| Cash | 3.24M | 3.23M | 7.57M | 13.38M | 53.96M |
| Total current liabilities | 0.90M | 0.72M | 2.09M | 7.63M | 11.09M |
| Net debt | -3.24M | -3.23M | -7.57M | -13.38M | -53.96M |
| Other stockholder equity | 280.11M | 276.34M | 275.72M | 269.63M | 263.35M |
| Property plant equipment | - | - | - | 1.22M | 1.47M |
| Total current assets | 4.63M | 4.22M | 8.02M | 14.82M | 55.46M |
| Long term investments | 5.35M | 5.35M | 5.35M | - | - |
| Net tangible assets | - | - | - | 10.45M | 48.25M |
| Net receivables | 1.00M | 0.56M | 0.00M | 0.10M | 0.10M |
| Inventory | - | - | - | 0.81M | 0.93M |
| Accounts payable | 0.51M | 0.39M | 1.20M | 2.97M | 1.83M |
| Accumulated other comprehensive income | - | - | -0.01M | -0.02M | -0.02M |
| Non currrent assets other | - | 5.35M | 5.35M | 2.04M | 2.41M |
| Non current assets total | 5.35M | 5.35M | 5.35M | 3.26M | 3.87M |
| Capital lease obligations | - | - | - | - | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 10.40M | 0.00M | 1.46M |
| Change to liabilities | - | - | - | 1.14M | 0.39M |
| Total cashflows from investing activities | - | - | 10.40M | - | 1.46M |
| Total cash from financing activities | 3.32M | 0.00M | 5.02M | 0.03M | 30.79M |
| Change to operating activities | - | - | - | -4.00M | 0.99M |
| Net income | -3.53M | -3.06M | -12.59M | -44.08M | -51.65M |
| Change in cash | 0.01M | -4.34M | -5.81M | -40.58M | -4.27M |
| Begin period cash flow | 3.23M | 7.57M | 13.38M | 53.96M | 58.23M |
| End period cash flow | 3.24M | 3.23M | 7.57M | 13.38M | 53.96M |
| Total cash from operating activities | -3.31M | -4.33M | -21.25M | -40.61M | -36.52M |
| Issuance of capital stock | 1.38M | 0.00M | 5.00M | 0.00M | 30.50M |
| Depreciation | - | - | 0.00M | 0.07M | 0.47M |
| Other cashflows from investing activities | - | - | 10.40M | - | - |
| Change to account receivables | -0.44M | -0.56M | 0.10M | 0.00M | 0.03M |
| Sale purchase of stock | -0.13M | 0.00M | - | - | - |
| Other cashflows from financing activities | 2.08M | - | 5.02M | 0.03M | 0.28M |
| Change to netincome | - | - | - | 6.25M | 13.25M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Change in working capital | -0.23M | -1.54M | -4.60M | -2.85M | 1.41M |
| Stock based compensation | 0.44M | 0.62M | 1.07M | 6.25M | 9.61M |
| Other non cash items | - | -0.36M | -4.05M | - | 0.88M |
| Free cash flow | -3.31M | -4.33M | -21.25M | -40.61M | -36.52M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.08 0.20% |
39.13 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.44 1.23% |
517.49 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.65 0.33% |
807.67 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
245 First Street, Riverview II, Cambridge, MA, United States, 02142
857 327 8778
1
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter M. Hecht Ph.D. | CEO & Director | 1964 |
| Ms. Cheryl Gault | Chief Operating Officer | 1980 |
| Ms. Anjeza Gjino | CFO & Corp. Sec. | 1983 |
| Dr. Todd Milne Ph.D. | Sr. VP of External Innovation | NA |
| Ms. Jessica Rennekamp | Associate Director of Corp. Communications | NA |
| Mr. Christopher Winrow Ph.D. | Sr. Director of Clinical Devel. & Neuroscience Program Lead | NA |
| Ms. Jennifer Chickering Ph.D. | Sr. Director of Clinical Strategy | NA |
| Dr. Regina Graul Ph.D. | President | NA |
| Ms. Rhonda M. Chicko | Chief Financial Officer | 1967 |
| Dr. Todd Milne Ph.D. | Senior Vice President of External Innovation | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.70%
Consumer Cyclical
-0.35%
Consumer Defensive
-0.54%
Energy
+0.40%
Financial Services
-0.54%
Financials
+0.30%
Healthcare
+0.19%
Industrials
+0.38%
Real Estate
+0.22%
Technology
+0.27%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...